KMT2A and carcinoma: Specifically, the KMT2 family of covalent histone modifiers (KMT2A, KMT2C, and KMT2D) was mutated in 12 of 88 (13.6%) carcinoids versus 16 of 60 (26.7%) carcinomas (p = 0.11), and the ARID family, involved in the SWI–SNF complex (ARID1A, ARID1B, and ARID2), had mutations in eight of 88 (9.0%) carcinoids versus six of 60 (10.0%) carcinomas (p = 1.0).